Final data from teva's pearl real-world study reinforce the long-term effectiveness of ajovy® (fremanezumab) for the prevention of chronic and episodic migraine

Tel aviv, israel, june 23, 2025 (globe newswire) -- teva pharmaceutical industries ltd. (nyse and tase: teva) today announced that the final analysis of the pan-european pearl phase 4 migraine prevention study showed that ajovy (fremanezumab), an anti-calcitonin gene-related peptide (cgrp) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1
TEVA Ratings Summary
TEVA Quant Ranking